Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.
Hepatitis C (HCV) coinfection is the leading cause of liver-related morbidity and is a leading cause of mortality in human immunodeficiency virus (HIV)-infected individuals in the antiretroviral therapy era. Direct-acting antiviral (DAA) therapies are transforming how HCV is treated with significant improvements in efficacy and tolerability. In this article, DAA agents expected to be available in 2014 are reviewed, including telaprevir, boceprevir, sofosbuvir, simeprevir, faldaprevir, and daclatasvir. Available data regarding clinical efficacy, adverse effects, and drug interactions in HIV-HCV coinfection are discussed. The management of adverse effects of HCV therapy and treatment considerations in patients with cirrhosis are also reviewed.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Virology
- Practice Guidelines as Topic
- Humans
- Hepatitis C, Chronic
- Hepacivirus
- HIV Infections
- Genotype
- Drug Therapy, Combination
- Coinfection
- Clinical Trials as Topic
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Virology
- Practice Guidelines as Topic
- Humans
- Hepatitis C, Chronic
- Hepacivirus
- HIV Infections
- Genotype
- Drug Therapy, Combination
- Coinfection
- Clinical Trials as Topic